Correction: ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Busines...
November 06 2019 - 4:50PM
Geneva, Switzerland and Boston, MA
–November 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN),
a biopharmaceutical company developing and commercializing novel
therapies to improve women’s reproductive health, today announced
that it will release results from the Phase 3 IMPLANT 4 clinical
trial of nolasiban and third quarter 2019 financial results on
Thursday, November 7, 2019. ObsEva management will host an
investment community conference call at 8 a.m. Eastern Time, 2
p.m. Central European Time, Thursday November 7, 2019, to discuss
these results.
Investors may participate by dialing (844)
419-1772 for U.S. callers or +1 (213) 660-0921 for international
callers, and referring to conference ID 9273485. A webcast of
the conference call can be accessed under the “Investors” section
of ObsEva’s website www.obseva.com.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical
company focused on the clinical development and commercialization
of novel therapeutics for serious conditions that compromise a
woman's reproductive health and pregnancy. Through strategic
in-licensing and disciplined drug development, ObsEva has
established a late-stage clinical pipeline with development
programs focused on treating endometriosis, uterine fibroids,
preterm labor and improving IVF outcomes. ObsEva is listed on the
NASDAQ Global Select Market and is trading under the ticker symbol
"OBSV" and on the SIX Swiss Exchange where it is trading under the
ticker symbol “OBSN”. For more information, please visit
www.ObsEva.com.
For further information, please
contact:
Media Contact Switzerland and
Europe:Christophe LampsDynamics Groupcla@dynamicsgroup.ch
+41 22 308 6220 Office+41 79 476 26 87 Mobile
Media Contact U.S.:Marion
JanicRooneyPartners LLCmjanic@rooneyco.com+1 212 223 4017 Office+1
646 537 5649 Mobile
CEO Office Contact:Shauna
DillonShauna.dillon@obseva.ch+41 22 552 1550
Investor Contact:Mario
CorsoSenior Director, Investor Relationsmario.corso@obseva.com+1
857 972 9347 Office+1 781 366 5726 Mobile
ObsEva (NASDAQ:OBSV)
Historical Stock Chart
From Mar 2024 to Apr 2024
ObsEva (NASDAQ:OBSV)
Historical Stock Chart
From Apr 2023 to Apr 2024